Sequential alkylating therapy and pembrolizumab induce near-complete response in high tumour mutational burden pancreatic neuroendocrine tumour: A case report

#4459

Introduction: Traditional treatment for neuroendocrine tumours (NETs), including surgery, somatostatin therapy, and targeted therapy, often fails in advanced disease. Alkylating therapy can increase tumour mutational burden (TMB), and the recent KEYNOTE-158 study approved pembrolizumab for advanced solid tumours with a high TMB.

Aim(s): This case aims to explore the potential benefit of sequential alkylating chemotherapy and immunotherapy in advanced pancreatic NET (pNET) with high TMB.

Materials and methods: Case information was extracted from our institutional electronic health record.

Conference:

Presenting Author:

Authors: Paranjpe I, Hornbacker K, Vadde S, Fisher G, Shaheen S,

Keywords: pancreatic neuroendocrine tumour, immunotherapy, pembrolizumab, tumour mutational burden, TMB,